骨细胞相关标志物在骨质疏松症和脆性骨折预测中的研究进展

Research progress of the osteocyte-related biomarkers in predicting osteoporosis and fragility fractures

由成骨细胞和破骨细胞分泌的传统骨转换标志物在骨质疏松症诊疗中发挥重要作用,但骨转换标志物在预测骨质疏松症及脆性骨折的应用上仍需深入研究。作为骨组织中含量最多的细胞,骨细胞在骨转换的调控中扮演重要角色。近来研究表明,由骨细胞分泌的骨转换标志物,如骨硬化蛋白、DKK1和成纤维细胞生长因子23有望成为骨质疏松症及脆性骨折预测的新型骨转换标志物。本文将对上述具有临床应用前景的骨细胞相关标志物在骨质疏松症和脆性骨折预测中的研究新进展进行简要概述,以期为骨质疏松症和脆性骨折的诊断和评估提供理论依据。

The traditional bone turnover markers derived from osteoblasts and osteoclasts are useful in the diagnosis and treatment of osteoporosis.However,the usefulness of bone turnover markers in predicting osteoporosis and fragility fractures remains elusive.As the most abundant cell in bone tissue,osteocytes play a central role in regulating bone turnover.Recent research shows that bone turnover markers secreted by osteocytes,such as sclerostin,DKK1,and fibroblast growth factor 23 could be a new type of bone turnover markers for osteoporosis and fragility fracture prediction.This paper will briefly summarize the new research progress of the osteocyte related biomarkers with clinical application prospects in the prediction of osteoporosis and fragility fracture,in order to provide theoretical basis for the diagnosis and evaluation of osteoporosis and fragility fractures.